- Home
- ARCT vs MLYS Comparison
ARCT vs MLYS Comparison
Compare ARCT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- MLYS
- Stock Information
- Founded
- ARCT 2013
- MLYS 2019
- Country
- ARCT United States
- MLYS United States
- Employees
- ARCT N/A
- MLYS N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- MLYS Health Care
- Exchange
- ARCT Nasdaq
- MLYS Nasdaq
- Market Cap
- ARCT 320.8M
- MLYS 890.6M
- IPO Year
- ARCT N/A
- MLYS 2023
- Fundamental
- Price
- ARCT $18.75
- MLYS $39.94
- Analyst Decision
- ARCT Strong Buy
- MLYS Strong Buy
- Analyst Count
- ARCT 10
- MLYS 6
- Target Price
- ARCT $50.88
- MLYS $42.60
- AVG Volume (30 Days)
- ARCT 493.8K
- MLYS 2.6M
- Earning Date
- ARCT 11-06-2025
- MLYS 11-10-2025
- Dividend Yield
- ARCT N/A
- MLYS N/A
- EPS Growth
- ARCT N/A
- MLYS N/A
- EPS
- ARCT N/A
- MLYS N/A
- Revenue
- ARCT $122,122,000.00
- MLYS N/A
- Revenue This Year
- ARCT N/A
- MLYS N/A
- Revenue Next Year
- ARCT $28.92
- MLYS N/A
- P/E Ratio
- ARCT N/A
- MLYS N/A
- Revenue Growth
- ARCT N/A
- MLYS N/A
- 52 Week Low
- ARCT $8.04
- MLYS $8.24
- 52 Week High
- ARCT $25.88
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- ARCT 63.54
- MLYS 85.52
- Support Level
- ARCT $17.70
- MLYS $34.59
- Resistance Level
- ARCT $19.50
- MLYS $39.20
- Average True Range (ATR)
- ARCT 1.05
- MLYS 3.04
- MACD
- ARCT -0.04
- MLYS 0.65
- Stochastic Oscillator
- ARCT 78.98
- MLYS 99.45
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.